Takeda’s Diabetes Drug Rival Faces Possible U.S. Recall
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's diabetes treatment could emerge a major victor if U.S. authorities order a recall of its major competitor, GlaxoSmithKline's Avandia (glimepiride)